IgAN: Seven Drugs, Five Mechanisms, One Crowded Market

IgA nephropathy is the best and worst story in biotech right now. Best for patients: the disease went from zero approved therapies to a shelf of seven drugs across five distinct mechanisms in under two years, after decades of nothing but blood pressure pills. Worst for investors: the same thing happened to everyone at once, so nobody owns a monopoly and everyone is fighting for share in a market the largest estimates put at only $3 billion. The question is not whether IgAN is investable. It is which name you own, and which mechanism actually wins.

The disease, sized honestly. IgAN is the most common primary glomerulonephritis worldwide. Galactose-deficient IgA1 antibodies form immune complexes that deposit in the kidney’s glomeruli, triggering inflammation and fibrosis. The published epidemiology ranges from roughly 150,000 to 217,000 US patients depending on the source, and 30% to 40% of diagnosed patients progress to end-stage renal disease within two decades, which is why a drug that slows decline is worth a lot to the patient even if it is not a $1 billion-plus drug for the manufacturer. The commercial market was pegged near $1.5 billion in 2025 and is growing around 18% a year as new drugs expand the treated population. That is real money. It is also a fraction of oncology, which is why the incumbents here are mid-caps and mega-cap divisions, not specialists betting the whole company.

Mechanism one: endothelin. Filspari owns the foundation. Travere’s Filspari (sparsentan) is the only drug in the field with a head-to-head Phase 3 against an active comparator. The PROTECT trial randomized 404 patients to sparsentan versus irbesartan, the blood pressure drug that was the old standard of care. Filspari cut proteinuria 49.8% from baseline at week 36 versus 15.1% for irbesartan (p<0.0001), and at the two-year mark slowed kidney function decline to an eGFR slope of -3.0 versus -4.2 mL/min/1.73m² per year, a 1.2-unit treatment effect with a p-value of 0.0168. The FDA converted it to full approval in September 2024, and KDIGO draft guidance positions it as foundational kidney-targeted therapy that can be combined with other mechanisms. Travere trades at $65.71 with a $6.19 billion market cap. Filspari carries a hepatotoxicity and embryo-fetal boxed warning with a REMS, so it is not frictionless, but it is the only drug here with proof it slows decline against a head-to-head control rather than placebo.

Mechanism two: the gut-targeted steroid. Calliditas’ Tarpeyo (budesonide) was the first modern IgAN drug to full approval, converting from accelerated to traditional in December 2023 on the NefIgArd trial. Its mechanism, a targeted-release corticosteroid that hits the gut where the pathogenic IgA is produced, is the cheapest and oldest-school approach in the group. Tarpeyo is now a legacy asset rather than a growth story, but it remains a comparator every new entrant has to be better than.

Mechanism three: complement. Two pharma giants, two different nodes. Novartis’ Fabhalta (iptacopan) won traditional approval on July 17, 2026, making it the first complement drug with full, eGFR-backed approval in IgAN, a step above the accelerated approvals held by its rivals. It is an oral complement factor B inhibitor, and it is the regulatory benchmark in the field. AstraZeneca’s Ultomiris (ravulizumab) is chasing the same cascade from a different angle, blocking C5 instead of factor B, and carries its own HSCT-TMA Phase 3 failure in July. The I CAN Phase 3 trial showed a 46.6% reduction in urine protein-creatinine ratio versus 5.6% on placebo at week 34, a 43.4% placebo-adjusted effect (p<0.0001), earning Priority Review with a PDUFA in Q4 2026. Both are divisions of mega-caps: Novartis at $301.9 billion and AstraZeneca at $257.4 billion, so neither approval moves a stock. The complement read-through matters as category validation, not as a trade. The friction to watch is real and differs by molecule: Fabhalta requires a REMS and pre-treatment vaccination against encapsulated bacteria because factor B blockade suppresses complement, while Ultomiris is an intravenous infusion every eight weeks, which is a real burden for a chronic kidney disease population already cycling through dialysis centers.

Mechanism four: the upstream BAFF/APRIL class. Two drugs, one winner. Vera’s Trutakna (atacicept) was the first dual BAFF/APRIL inhibitor approved, via accelerated approval on July 7, 2026, on a 46% proteinuria reduction in ORIGIN 3. Vertex’s povetacicept is the second, with a November 30 PDUFA, and its RAINIER data delivered a 52% proteinuria reduction, 49.8% placebo-adjusted (p<0.0001), plus a 77.4% drop in serum galactose-deficient IgA1, the disease-driving antibody, the largest reduction reported in the field. Both drugs hit the upstream driver of autoantibody production. The dosing is the differentiator: Trutakna is weekly subcutaneous, while povetacicept is every four weeks. For a chronic disease, that convenience gap matters.

Mechanism five: the APRIL single. Voyxact, technically excellent, practically untradeable. Otsuka’s Voyxact (sibeprenlimab) blocks APRIL alone rather than BAFF plus APRIL. Its VISIONARY trial delivered the cleanest proteinuria number in the group at nine months, a 50.2% reduction versus a 2.1% increase on placebo, and a 12-month eGFR treatment effect of +5.5 mL/min/1.73m². The problem is the vehicle. Voyxact belongs to Otsuka Holdings, which trades as an over-the-counter ADR at $34.41 with no reliable market cap through US data providers, the same liquidity trap that keeps most American investors out of Japanese pharma.

The accelerated-versus-traditional gap is the real story. Three drugs here hold full, traditional approval: Filspari, Tarpeyo, and Fabhalta. Two hold accelerated approval and are still on the hook for confirmatory eGFR data: Trutakna and Voyxact. That distinction is worth more than any mechanism nuance, because an accelerated approval can be withdrawn if the confirmatory trial fails. Vera’s ORIGIN 3 eGFR readout, expected in Q3 2026, is the highest-stakes binary catalyst in the whole field. If it confirms a meaningful slowing of kidney function decline, Trutakna converts to full approval and closes the gap with Fabhalta. If it disappoints, the “accelerated” asterisk becomes a liability and the $2.33 billion market cap Vera carries gets stress-tested.

The risks. This is a zero-sum share battle: seven drugs, five mechanisms, one formulary. Payers will not cover all of them, and the loser is whichever entrant cannot point to a hard eGFR number. Cross-trial comparisons are the only comparisons anyone has, because nobody has run a head-to-head outside PROTECT, and the proteinuria reductions across the group, from Trutakna’s 46% to Voyxact’s 50.2% to povetacicept’s 52%, are close enough that mechanism evangelism, not data, may decide share. The confirmatory readouts carry real binary risk for the accelerated names, and Vera’s specifically lands within weeks. The market is smaller than the enthusiasm: even at the high end, seven drugs fighting over $3 billion means the median entrant peaks below $500 million, which is why only Travere and Vera among the pure plays can actually re-rate on this indication.

The verdict. If you want the one name that already has durable proof and a head-to-head win, it is Travere at $6.19 billion: Filspari is the foundational drug the others get stacked on top of, and its full approval means no confirmatory overhang. If you want the highest-torque binary, it is Vera at $2.33 billion heading into ORIGIN 3; the stock re-rates hard on a clean eGFR readout and de-rates hard on a miss, so size it like a catalyst bet, not a core holding. Vertex’s povetacicept is the best drug that does not matter: strong data, but a rounding error on a $138.9 billion market cap. And Voyxact is a fine mechanism trapped in an untradeable ADR. The winner is not a mechanism. It is whoever converts to full approval first and proves the kidney, not just the urine, gets better.

Sources: AstraZeneca Ultomiris I CAN press release, ClinicalTrials.gov NCT06291376, Travere PROTECT full-approval release.